Overview


According to FutureWise analysis the market for human insulin is expected to register a CAGR of 8.32% from 2023-2031.

An insulin is a hormone produced by the beta cells in the pancreas. This hormone helps to regulate blood glucose levels. The organ controls body systems and regulates the uptake of amino acids by body cells. Insulin is essential for the body's absorption of glucose. Diabetic people have a high blood sugar level or high glucose level because their blood sugar is too high. Diabetes damages the blood vessels, causing life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. Type 1 diabetes is a condition in which the body does not produce enough insulin to control blood sugar levels. Diabetics take insulin daily to control their blood sugar levels. Increasing prevalence of diabetes is the primary factor contributing to the growth of the global human insulin market. Among the factors contributing to increasing numbers of diabetic patients globally are changes in lifestyles, obesity rates, geriatric populations as well as inadequate healthcare services.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Human Insulin Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Human Insulin Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • B. Braun Melsungen AG
  • Biocon Limited
  • Biodel Inc.
  • Becton, Dickinson and Company
  • ELI Lilly and Company
  • Julphar (Also Known as Gulf Pharmaceutical Industries)
  • NOVO Nordisk A/S
  • Sanofi
  • Wockhardt Limited
  • Ypsomed AG

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • HI Drugs
  • HI Delivery Devices

By Type

  • Insulin Analogs and Biosimilars
    • Long-Acting Biosimilars
    • Rapid-Acting Biosimilars
    • Premixed Biosimilars
  • HI Biologics
    • Short-Acting Biologics
    • Intermediate-Acting Biologics
    • Premixed Biologics

By Brand

  • HI Analogs and Biosimilars
    • Lantus
    • Novorapid and Novolog
    • Humalog
    • Other Brands
  • HI Biologics
    • Actrapid, Mixtard, and Insulatard
    • Humulin
    • Insuman

By Delivery Devices

  • Syringes
  • Pens
    • Disposable Pens
    • Reusable Pens
  • Pen Needles
    • Standard Pen Needles
    • Safety Pen Needles

By Application

  • Type I Diabetes
  • Type II Diabetes

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Human Insulin Market By Product Type, By Type, By Brand, By Delivery Devices, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Human Insulin Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Human Insulin Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Human Insulin Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Human Insulin Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. HI Drugs
        2. HI Delivery Devices

  • 8.   Human Insulin Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Insulin Analogs and Biosimilars
         1.1. Long-Acting Biosimilars
         1.2. Rapid-Acting Biosimilars
         1.3. Premixed Biosimilars
        2. HI Biologics
         2.1. Short-Acting Biologics
         2.2. Intermediate-Acting Biologics
         2.3. Premixed Biologics

  • 9.   Human Insulin Market, By Brand Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. HI Analogs and Biosimilars
         1.1. Lantus
         1.2. Novorapid and Novolog
         1.3. Humalog
         1.4. Other Brands
        2. HI Biologics
         2.1. Actrapid, Mixtard, and Insulatard
         2.2. Humulin
         2.3. Insuman

  • 10.   Human Insulin Market, By Delivery Devices Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Syringes
        2. Pens
         2.1. Disposable Pens
         2.2. Reusable Pens
        3. Pen Needles
         3.1. Standard Pen Needles
         3.2. Safety Pen Needles

  • 11.   Human Insulin Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Type I Diabetes
        2. Type II Diabetes

  • 12.   North America Human Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 13.   Latin America Human Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 14.   Europe Human Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 15.   Asia Pacific Human Insulin Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 16.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 17.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 18.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. B. Braun Melsungen AG
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Biocon Limited
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Biodel Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Becton, Dickinson and Company
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ELI Lilly and Company
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Julphar (Also Known as Gulf Pharmaceutical Industries)
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. NOVO Nordisk A/S
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Sanofi
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Wockhardt Limited
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
          10. Ypsomed AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 19.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11